Severe thrombocytopenia induced by trastuzumab rechallenge: a case report and literature review

Trastuzumab can significantly prolong the survival of patients with human epidermal growth factor receptor‐2 (HER‐2)‐positive breast cancer. Trastuzumab‐induced thrombocytopenia is a rare adverse effect. There have been no reports of acute, grade 4 thrombocytopenia after weekly trastuzumab therapy. The study reports a case of a breast cancer patient with severe thrombocytopenia due to trastuzumab infusion (8 mg/kg). Moreover, the patient experienced recurrence of severe thrombocytopenia after receiving weekly trastuzumab therapy (4 mg/kg).

[1]  Changsheng Ye,et al.  Thrombocytopenia Induced by Herceptin , 2019, The American surgeon.

[2]  D. Stover,et al.  Inhibition of Megakaryocyte Differentiation by Antibody–Drug Conjugates (ADCs) is Mediated by Macropinocytosis: Implications for ADC-induced Thrombocytopenia , 2017, Molecular Cancer Therapeutics.

[3]  M. Miarons,et al.  Gradual thrombocytopenia induced by long‐term trastuzumab exposure , 2016, Journal of clinical pharmacy and therapeutics.

[4]  Jong-Hyeon Jeong,et al.  Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. Sliwkowski,et al.  Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1) , 2014, Clinical Cancer Research.

[6]  M. Pino,et al.  Severe thrombocytopenia after trastuzumab retreatment: a case report , 2013, BMC Research Notes.

[7]  H. Gogas,et al.  Severe thrombocytopenia related to trastuzumab infusion , 2011, Medical science monitor : international medical journal of experimental and clinical research.

[8]  L. Gianni,et al.  Trastuzumab-related thrombocytopenia: always a self-limiting complication? , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  R. Cathomas,et al.  Severe drug-induced thrombocytopenia after treatment with trastuzumab but not with lapatinib. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  C. Jara Sánchez,et al.  Drug-induced thrombocytopenia induced by trastuzumab: a special challenge in a curable disease. , 2009, Annals of Oncology.

[11]  C. Palmieri,et al.  Severe thrombocytopenia induced by a single infusion of trastuzumab. , 2008, Clinical breast cancer.

[12]  T. Warkentin,et al.  Focus on Research: Drug-Induced Immune-Mediated Thrombocytopenia — From Purpura to Thrombosis , 2007 .

[13]  R. Aster,et al.  Drug-induced immune thrombocytopenia. , 2007, The New England journal of medicine.

[14]  J. George,et al.  Drug-induced thrombocytopenia: a systematic review of published case reports. , 1998, Annals of internal medicine.